Literature DB >> 19002161

Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo.

Ryan L Boudreau1, Inês Martins, Beverly L Davidson.   

Abstract

RNA interference (RNAi) provides a promising therapeutic approach to human diseases. However, data from recent reports demonstrate that short-hairpin RNAs (shRNAs) may cause cellular toxicity, and this warrants further investigation of the safety of using RNAi vectors. Earlier, in comparing hairpin-based RNAi vectors, we noted that shRNAs are highly expressed and yield an abundance of unprocessed precursors, whereas artificial microRNAs (miRNAs) are expressed at lower levels and are processed efficiently. We hypothesized that unprocessed shRNAs arise from the saturation of endogenous RNAi machinery, which poses likely a burden to cells. In this study, we tested that hypothesis by assessing the relative effects of shRNAs and artificial miRNAs on the processing and function of miRNAs. In competition assays, shRNAs disrupted miRNA biogenesis and function, whereas artificial miRNAs avoided this interference even when dosed to silence as effectively as shRNAs. We next compared the safety of these vectors in mouse cerebella, and found that shRNAs cause Purkinje cell neurotoxicity. By contrast, artificial miRNA expression was well tolerated, resulting in effective target gene silencing in Purkinje cells. These findings, together with data from earlier work in mouse striata, suggest that miRNA-based platforms are better suited for therapeutic silencing in the mammalian brain.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19002161      PMCID: PMC2834985          DOI: 10.1038/mt.2008.231

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  34 in total

1.  Asymmetry in the assembly of the RNAi enzyme complex.

Authors:  Dianne S Schwarz; György Hutvágner; Tingting Du; Zuoshang Xu; Neil Aronin; Phillip D Zamore
Journal:  Cell       Date:  2003-10-17       Impact factor: 41.582

2.  Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells.

Authors:  Yan Zeng; Eric J Wagner; Bryan R Cullen
Journal:  Mol Cell       Date:  2002-06       Impact factor: 17.970

Review 3.  Gene silencing in mammals by small interfering RNAs.

Authors:  Michael T McManus; Phillip A Sharp
Journal:  Nat Rev Genet       Date:  2002-10       Impact factor: 53.242

4.  Induction of an interferon response by RNAi vectors in mammalian cells.

Authors:  Alan J Bridge; Stephanie Pebernard; Annick Ducraux; Anne-Laure Nicoulaz; Richard Iggo
Journal:  Nat Genet       Date:  2003-07       Impact factor: 38.330

5.  Ribonuclease activity and RNA binding of recombinant human Dicer.

Authors:  Patrick Provost; David Dishart; Johanne Doucet; David Frendewey; Bengt Samuelsson; Olof Rådmark
Journal:  EMBO J       Date:  2002-11-01       Impact factor: 11.598

6.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells.

Authors:  S M Elbashir; J Harborth; W Lendeckel; A Yalcin; K Weber; T Tuschl
Journal:  Nature       Date:  2001-05-24       Impact factor: 49.962

7.  Insect cells as a factory to produce adeno-associated virus type 2 vectors.

Authors:  Masashi Urabe; Chuantian Ding; Robert M Kotin
Journal:  Hum Gene Ther       Date:  2002-11-01       Impact factor: 5.695

8.  siRNA-mediated gene silencing in vitro and in vivo.

Authors:  Haibin Xia; Qinwen Mao; Henry L Paulson; Beverly L Davidson
Journal:  Nat Biotechnol       Date:  2002-09-16       Impact factor: 54.908

9.  Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs.

Authors:  Ryan L Boudreau; Alex Mas Monteys; Beverly L Davidson
Journal:  RNA       Date:  2008-08-12       Impact factor: 4.942

10.  The nuclear RNase III Drosha initiates microRNA processing.

Authors:  Yoontae Lee; Chiyoung Ahn; Jinju Han; Hyounjeong Choi; Jaekwang Kim; Jeongbin Yim; Junho Lee; Patrick Provost; Olof Rådmark; Sunyoung Kim; V Narry Kim
Journal:  Nature       Date:  2003-09-25       Impact factor: 49.962

View more
  161 in total

Review 1.  Subcellular fate and off-target effects of siRNA, shRNA, and miRNA.

Authors:  Saurabh Singh; Ajit S Narang; Ram I Mahato
Journal:  Pharm Res       Date:  2011-10-28       Impact factor: 4.200

2.  Identifying functional microRNAs in macrophages with polarized phenotypes.

Authors:  Joel W Graff; Anne M Dickson; Gwendolyn Clay; Anton P McCaffrey; Mary E Wilson
Journal:  J Biol Chem       Date:  2012-05-01       Impact factor: 5.157

3.  Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease.

Authors:  Ryan L Boudreau; Ryan M Spengler; Beverly L Davidson
Journal:  Mol Ther       Date:  2011-09-27       Impact factor: 11.454

4.  Artificial mirtron-mediated gene knockdown: functional DMPK silencing in mammalian cells.

Authors:  Yiqi Seow; Christopher R Sibley; Matthew J A Wood
Journal:  RNA       Date:  2012-05-30       Impact factor: 4.942

5.  Double-stranded Let-7 mimics, potential candidates for cancer gene therapy.

Authors:  Qi-zhao Wang; Ying-hui Lv; Yu-hua Gong; Zhao-fa Li; William Xu; Yong Diao; Ruian Xu
Journal:  J Physiol Biochem       Date:  2011-11-09       Impact factor: 4.158

Review 6.  Therapy development in Huntington disease: From current strategies to emerging opportunities.

Authors:  Audrey S Dickey; Albert R La Spada
Journal:  Am J Med Genet A       Date:  2017-12-08       Impact factor: 2.802

Review 7.  Gene therapy to treat cardiac arrhythmias.

Authors:  Rossana Bongianino; Silvia G Priori
Journal:  Nat Rev Cardiol       Date:  2015-04-28       Impact factor: 32.419

Review 8.  Short non-coding RNA biology and neurodegenerative disorders: novel disease targets and therapeutics.

Authors:  Marc S Weinberg; Matthew J A Wood
Journal:  Hum Mol Genet       Date:  2009-04-15       Impact factor: 6.150

9.  RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1.

Authors:  Megan S Keiser; James C Geoghegan; Ryan L Boudreau; Kim A Lennox; Beverly L Davidson
Journal:  Neurobiol Dis       Date:  2013-04-10       Impact factor: 5.996

10.  Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects.

Authors:  Christina E Khodr; Amanda Becerra; Ye Han; Martha C Bohn
Journal:  Brain Res       Date:  2014-01-21       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.